Fondaparinux Sodium Vs Low-Molecular-Weight Heparin For Deep Vein Thrombosis During THA .
A Comparison Between Fondaparinux Sodium and Low-Molecular-Weight Heparin in Preventing Patients Undergoing Hip Replacement from Deep Vein Thrombosis.
J Musculoskelet Neuronal Interact . 2024 Jun 1;24(2):185-191.Sixty patients undergoing total hip arthroplasty were randomized to receive either fondaparinux sodium (n=30) or low-molecular-weight heparin (n=30). Outcomes of interest included the incidence of deep vein thrombosis (DVT) after surgery, Wells scores, subcutaneous ecchymosis, swelling circumference, and Visual Analogue Scale (VAS) pain scores. Outcomes were assessed at 3, 5, and 7 days postoperatively. Overall, the results of the study revealed that fondaparinux sodium was more effective than low-molecular-weight heparin in reducing the incidence of DVT, subcutaneous ecchymosis, and swelling circumference by the seventh day after surgery. The findings suggest that fondaparinux sodium may be a superior option for preventing postoperative DVT in patients undergoing total hip arthroplasty.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
